NeuraNova

Executive Summary

NeuraNova is a Boston-based medical device startup addressing the critical challenge of rapid stroke detection. Founded in 2021, the company is developing a portable, point-of-care diagnostic device that aims to reduce time-to-treatment by enabling brain monitoring outside hospital settings. With stroke being a leading cause of disability and death, every minute saved can significantly improve patient outcomes. NeuraNova’s technology leverages innovative sensors and algorithms to provide real-time, non-invasive assessment of cerebral health, potentially transforming emergency response and rural healthcare access. The device is designed to be cost-effective and easy to use, targeting paramedics, urgent care centers, and clinics. As a private company in the Approved stage, NeuraNova is poised for near-term commercialization but lacks disclosed funding or valuation details. The market for stroke diagnostics is large, and success depends on regulatory clearances, clinical validation, and strategic partnerships. While competition exists from established players, NeuraNova’s focus on portability and speed offers a distinct value proposition. The company’s ability to execute on upcoming milestones will determine its trajectory in this competitive landscape.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance for First Device75% success
• Q3 2026Series A Funding Announcement70% success
• Q4 2026Clinical Validation Study Results60% success